Business
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand
New $138 million facility at GE HealthCare’s Cork manufacturing site will enable 25 million more patient doses of contrast media per year by the end of 2027i
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nNew $138 million facility at GE HealthCare’s Cork manufacturing site will enable 25 million more patient doses of contrast media per year by the end of 2027i\n\n\n\nDemand for CT and X-Ray contrast media, used to enhance medical imaging procedures globally, is estimated to double in the next ten yearsii\n\n\n\nInvestment will create additional capacity to cater for growing demand, while offering increased flexibility and resiliency for security of supply\n\n\n\n CHALFONT ST. GILES, England--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire)\nContrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, along with GE HealthCare’s other fill and finish production sites in Shanghai, China, and Oslo, Norway, supplied over 100 million patient doses of contrast media around the worldiii.\n\n\nThe new 3000m2 facility - which will support both established and pipeline products – will include solution preparation vessels, multi-functional powder handling systems, a new filling line and autoclaves, with advanced automation systems underpinning production. Once established, the additional capacity will cater for the growing global demand, while offering increased flexibility and resiliency across GE HealthCare’s contrast media production network for security of supply.\n\n\nPresident & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, Kevin O’Neill, said, “As an industry leader we have a responsibility to help meet the growing glob...